{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T02:54:21Z","timestamp":1761706461217,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5,9]]},"DOI":"10.1182\/bloodadvances.2022009177","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T18:35:05Z","timestamp":1668105305000},"page":"1926-1928","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Curing CLL: one clone at a time"],"prefix":"10.1182","volume":"7","author":[{"given":"Burcu","family":"Aslan","sequence":"first","affiliation":[{"name":"1Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8732-562X","authenticated-orcid":false,"given":"Shady I.","family":"Tantawy","sequence":"additional","affiliation":[{"name":"1Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varsha","family":"Gandhi","sequence":"additional","affiliation":[{"name":"1Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"9","key":"2023050915233514000_bib1","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","article-title":"Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance","volume":"7","author":"Naeem","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2023050915233514000_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"2023050915233514000_bib3","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023050915233514000_bib4","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41375-021-01123-6","article-title":"BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib","volume":"35","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Leukemia"},{"issue":"10277","key":"2023050915233514000_bib5","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"2023050915233514000_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00675-9","article-title":"Pirtobrutinib inhibits wild-type and mutant Bruton\u2019s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia","volume":"12","author":"Aslan","year":"2022","journal-title":"Blood Cancer J"},{"issue":"8","key":"2023050915233514000_bib7","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"2023050915233514000_bib8","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2023050915233514000_bib9","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2022-171119","article-title":"Pharmacological profiling of cells from patients with chronic lymphocytic leukemia (CLL) treated with pirtobrutinib [abstract]","volume":"140","author":"Tantawy","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2023050915233514000_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00467-7","article-title":"Ibrutinib combinations in CLL therapy: scientific rationale and clinical results","volume":"11","author":"Timofeeva","year":"2021","journal-title":"Blood Cancer J"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/9\/1926\/2049167\/blooda_adv-2022-009177-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/9\/1926\/2049167\/blooda_adv-2022-009177-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T16:19:02Z","timestamp":1701361142000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/9\/1926\/487061\/Curing-CLL-one-clone-at-a-time"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,5,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009177","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2023,5,9]]}}}